Cancer - Kidney(구연) (E-082) 신장암에서 Everolimus 와 Metformin 의 복합 치료 효과 ¹한양대학교 의과대학 비뇨의학교실 ²한양대학교 의생명공학전문대학원 임상의과학과 이지영¹,황현지¹·², 홍성휘¹, 장은비¹·², 박성열¹, 문홍상¹, 윤영은¹* Metformin is one of the first-line treatment for type 2 diabetes. Recently, metformin has been reported to inhibit the growth and metastasis of cancer. However, the anticancer effects of metformin in kidney cancers has not been revealed. In this study, we investigate the anticancer effect of metformin on clear cell kidney cancer and the possible synergic effect of metformin and mTOR inhibitor. Animal experiments were performed in accordance with the federal guidelines for animal experimentation. After forming a tumor by an 5x106 s.c injection of Caki-1 cells. Mice were injected oral gavage with metformin (150mg/kg) and everolimus (10mg/kg) after 1month sacrifice. We have previously obtained results that cell proliferation is reduced when everolimus and metformin are treated together through cell-proliferation assays. We checked the manifestation of genes related to mTOR pathway, the signalling pathway targeted by everolimus. The expression of p-mTOR and its downstream genes, p-p70s6k and p-4EBP1, were better when metformin was treated together than when everolimus alone. Next, we made xenograft model using RCC cell. To further confirm the role of everolimus and metformin in a relative in vivo setting, we injected Caki-1 cells into Balb/c nude mice. The tumor volume, weight and size were all reduced when co-treated with metformin. Metformin and everolimus showed anticancer effect in clear cell kidney cancer cell lines. Especially, two drugs showed strong synergic effect when treated in same time. These results suggest a new alternative to kidney cancer treatment. keywords : RCC, Everolimus, Metformin